Agoracom Blog

Mountain Valley MD $MVMD.ca Proceeding With COVID-19 Clearance Trial in Level 4 Biohazard Facility $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:11 AM on Wednesday, January 27th, 2021
  • Lab study to demonstrate solubility technology applied to the Ivermectin drug can be applied as a broad therapeutic to immediately treat COVID-19
  • Commencing lab trial in late February 2021, with results anticipated in April 2021.

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) is pleased to announce it has executed an agreement to conduct its Bio Safety Level 4 (“BSL-4”) lab study of COVID-19 viral clearance in transgenic mice designed to prove the superiority of the Company’s solubilized Ivermectin technology versus commercially available oral form in speed and efficacy of viral clearance.  The agreement was signed January 26, 2021.

“This is a very significant project for MVMD and it will clearly demonstrate how our solubility technology applied to the Ivermectin drug can be applied as a broad therapeutic to immediately treat COVID-19, as well as its role in stopping the deadly spread of future pandemics that are certain to follow,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “Quicksol™ allows us to imagine a world’s first as an injectable Ivermectin format for emergency front line usage as well as a rapid dissolve tablet that is administered for prevention like vitamin C around the world.”

There are less than thirty BSL-4 facilities in the world capable of performing this study and it is not unusual for projects to take up to three years to schedule.  The Company was able to demonstrate the significance of its patented solubilized Ivermectin technology through its presentation of the superior pharmacokinetic data documented from two previously completed pre-clinical trials and was granted approval by the BSL-4 facility to commence this trial in late February 2021.  The study results are anticipated in April 2021.

This study will be the first of its kind ever conducted with human grade solubilized Ivermectin anywhere in the world and its design was led by the Company’s key scientific advisor, Dr. John Clements.  Dr. Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine and has over 35 years of experience in vaccine, immunology and infectious diseases research and development, with a distinguished scientific career focused on developing and evaluating vaccines for a wide range of infectious diseases globally.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/754031-mountain-valley-md-proceeding-with-covid-19-clearance-trial-in-level-4-biohazard-facility/messages/2300498#message

Tags: , , , , , ,

Comments are closed.